CFMG & Wellpath in California — a documentary investigation · Article 025 of 100 · Series 3 — Physician executives, ownership and succession

Scott Kennedy and the Financial Side of Physician Governance

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Scott Kennedy and the Financial Side of Physician Governance is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: What does a physician CFO/director potentially reveal about management fees, bankruptcy, and board oversight? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Why this is analytically important#

If the underlying filings truly say what the docket text says, the record raises an obvious question:

How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?

There may be an innocent explanation: ECF relationship categories may have been selected imperfectly, the disclosure might have been drafted for conflicts purposes rather than corporate genealogy, or docket metadata may compress a more nuanced statement.

the record must not turn this into an accusation before reviewing the filings themselves.

But the repetition across more than one case means the issue is sufficiently concrete to justify a dedicated source-retrieval project.

open question: Very High.

Requested source set:

• exact PDF of interested-entity/corporate-disclosure filings in Beckner ;

• exact filings in Sand ;

• exact filings in Strieter ;

• exact filings in Avila ;

• equivalent filings in Venegas , Kukar-Tekano , Ayala , Pugh , and current CFMG cases.

The output should be a year-by-year table showing the relationship box or terminology actually used.

The contract record shows a recurring county-side misdescription#

Multiple county/public sources use formulations such as:

• “CFMG dba Wellpath”

• “CFMG/Wellpath”

• “CFMG, now Wellpath”

• “Wellpath, formerly CFMG”

• “CFMG dba Wellpath Management, Inc.”

• “CFMG commonly known as Wellpath”

These formulations should not be collapsed into one legal proposition.

They may represent:

• brand usage;

• County shorthand;

• vendor-system nomenclature;

• mistaken corporate succession assumptions;

• or actual contractual DBA language.

The federal bankruptcy record proves why this matters: CFMG remained a distinct professional corporation.

Thus county nomenclature is best treated as:

evidence of how the healthcare operation presented itself and was understood by the governmental client.

That is highly relevant to operational identity.

It is not enough to establish corporate genealogy.

Scott kennedy enters the public CFMG corporate record#

Scott Herbert Kennedy, M.D., appears in the post-Herr CFMG structure.

An El Dorado County contract record from late 2022 identifies:

• Bazzel as President;

• Kennedy as Vice President/Treasurer.

By January 2025, the California Secretary of State identifies Kennedy as:

• Chief Financial Officer

• Director

He therefore clearly held formal CFMG corporate authority by 2025.

However, unlike Bazzel and Medrano, the present public source set does not yet permit the investigation to reconstruct Kennedy's pre-CFMG Wellpath/CCS role with equal confidence.

That gap should remain explicit.

the record should not infer a particular Wellpath executive history simply because Kennedy's CFMG address and email infrastructure are associated with the Wellpath enterprise.

The public governance record actually contains strong defense evidence#

An objective CPOM record must recognize that the governance history contains evidence supporting the legality of the structure.

• CFMG consistently existed as a separate California professional corporation.

• Physician presidents signed major county agreements.

• Current directors are physicians.

• CFMG remained a nondebtor PC during Wellpath bankruptcy.

• Post-bankruptcy contracts continue to be signed in CFMG's name.

• Wellpath publicly says CFMG is physician-owned.

• Hallman publicly said there was no ownership overlap.

• County contracts invoke ordinary corporate-signature formalities.

• The current Secretary of State filing names physician directors rather than Wellpath's nonphysician executive board.

These facts weigh against a simplistic "shell company" narrative.

Corporate disclosures — affiliate/parent labels as source-tracing material#

Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

These are useful for establishing that a disclosed corporate relationship existed or was represented.

They are poor substitutes for:

• stock ledgers;

• shareholder agreements;

• capitalization tables;

• governance instruments;

• or the MSA.

A Rule 7.1 label should therefore be coded:

relationship representation — authenticate underlying corporate basis.

Exact disclosure language is reproduced here only with:

• case;

• ECF number;

• filing date;

• filing party;

• signatory;

• and surrounding form context.

II. Structural and Historical Context#

2019: the CFMG management agreement moves to Wellpath LLC#

The next public document is more precise.

Effective January 1, 2019, the parties executed an Assignment of Management Services Agreement .

The document identifies:

• California Forensic Medical Group, Inc. as the Company ;

• Wellpath LLC as the Manager ; and

• Wellpath Management, Inc., with its predecessor names, as the Outgoing Manager .

The assignment says the October 2018 corporate transaction made the entities affiliates and states that the MSA was being transferred to Wellpath LLC for efficiency in administering management functions. 2019 Assignment

That document is one of the clearest public markers of the transition into the Wellpath era.

It is also significant for another reason: the assignment states that the MSA was transferred together with related or incidental instruments, including relevant stock-transfer restriction agreements .

The assignment proves that such instruments were part of the transaction documents or related contractual architecture.

It does not reveal their operative terms.

That makes the underlying CFMG-specific stock-transfer and succession documents an important open-source target rather than a basis for speculation.

Records that would resolve the question#

• Actual Rule 7.1 / interested-entity PDFs from Beckner , Sand , Avila , Strieter , and post-bankruptcy CFMG cases.

• Every Overfield exhibit concerning Chapman termination.

• Chapman’s continued deposition once filed.

• Any renewed Hole deposition.

• Complete Smith same-entity stipulation and financial discovery record.

• Complete D.M. discovery correspondence supporting the same-functions representation.

• Complete Andrew Ho bankruptcy/arbitration references; public filings only.

• Napa Agreement 190201B and every amendment.

• County-by-county executed agreements and RFP proposals.

• CFMG/Wellpath quality-review policies implicated by Kartchner .

• Bankruptcy insurance/indemnity schedules naming CFMG.

• The 2012 MSA exhibits and every later amendment.

• All stock-transfer restriction / succession instruments referenced by the 2019 assignment.

• CFMG bylaws and shareholder/officer history.

• Physician employment templates pre-2018 vs post-2018.

• Wellpath enterprise clinical-policy approval matrices for California.

III. The Control and Governance Analysis#

Documents with the highest evidentiary value#

the investigation should prioritize obtaining and authenticating:

• complete December 31, 2012 MSA;

• all amendments and restatements;

• 2019 assignment documents;

• stock-transfer restriction agreements;

• shareholder succession / replacement agreements;

• CFMG articles, bylaws, shareholder agreements, and board minutes;

• complete list of CFMG shareholders/directors/officers by year;

• “Company Designee” appointments;

• Wellpath/CFMG delegation-of-authority matrices;

• physician hiring and termination workflows;

• physician compensation approval matrices;

• HRIS and payroll audit trails;

• EHR ownership and administrator records;

• clinical policy approval metadata;

• county RFP responses describing management hierarchy;

• malpractice/GL coverage and indemnity instruments;

• outside-counsel retention/claims administration protocols;

• quality assurance and mortality-review governance documents;

• management-fee and intercompany accounting records;

• post-bankruptcy amendments or succession instruments.

Subpages#

• Corporate timeline: 1983–2026

• The 2012 Management Services Agreement

• H.I.G. Capital and the 2013 investment

• The 2018 CCS–CMGC transaction and creation of Wellpath

• The 2019 management assignment

• CFMG physician ownership and governance

• California county contracts

• Physician employment and HR control

• Physician compensation and payroll

• Medical records and EHR control

• Clinical policy and operational control

• Litigation defense and claims administration

• Pre-bankruptcy litigation positions

• Bankruptcy and the rediscovery of CFMG

• Post-bankruptcy California litigation

• Smith v. Santa Cruz County

• D.M. v. County of Merced

• Hernandez v. County of Monterey

• Overfield v. Wellpath / CFMG

• Fresno case study: Miles, Henderson, and J.S.

• California CPOM law and 2026 enforcement

• Evidence matrix

• Case index

• Primary-document library

• Open questions / records not yet public

Every page should include a visible Evidence Level badge and a What this does not prove section.

Why these documents matter now#

California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:

• replace a physician shareholder;

• control who succeeds the shareholder;

• make physician ownership dependent on continued use of the MSO;

• prevent the physician practice from replacing the MSO without risking ownership.

That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.

The decisive questions are:

• Who could become a CFMG shareholder?

• Who nominated or approved successors?

• Could Wellpath veto a proposed physician shareholder?

• Could Wellpath require replacement of a physician shareholder?

• What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?

• Was any stock held in escrow?

• Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?

• Who fixed the share-purchase price?

• Who funded the purchase?

• Did Wellpath or an affiliate possess a security interest tied to the shares?

• Could a physician owner remain owner after terminating the MSA?

• Could the physician owner sell to another qualified physician without Wellpath approval?

Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

The bankruptcy creates a natural experiment#

The 2024–2025 bankruptcy is analytically valuable because the manager enterprise underwent an extraordinary stress event while CFMG remained outside the debtor group.

That creates a natural experiment:

What happened to CFMG when its exclusive MSO entered Chapter 11 and changed ownership?

Questions:

• Did CFMG hold a board meeting to evaluate replacing Wellpath?

• Was any alternative MSO considered?

• Did CFMG approve assumption/continuation of the MSA?

• Were fees amended?

• Were stock-transfer restrictions reaffirmed?

• Did lender ownership require CFMG consent?

• Did CFMG obtain independent legal advice?

• Did the Company Designee approve transition?

• Did post-emergence documents ratify Wellpath LLC as manager?

This may be the best period for testing whether CFMG had practical independence.

If no alternative was considered, that fact is not proof of control; staying with Wellpath may have been commercially sensible.

But the governance record should reveal whether CFMG exercised a choice.

The same governance record also justifies deeper control review#

Other facts justify investigation rather than a presumption of independence:

• The original MSA was signed by the same CEO on both sides.

• H.I.G. was included in the MSA notice architecture from inception.

• The manager may attend and participate in CFMG governance meetings.

• Company action can be concentrated through a single Company Designee.

• The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.

• Bazzel came from the pre-merger CCS executive structure.

• Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.

• CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.

• Current officers/directors use the same Tennessee administrative locus.

• Current shareholders remain undisclosed in the public evidence.

• The actual stock-succession rules remain missing.

Again, those facts do not establish illegality.

They identify the precise governance records needed to answer the question.

"PATIENT SAFETY" IS WHERE ORDINARY HR AND PHYSICIAN GOVERNANCE MEET#

Where a termination or separation communication invokes clinical safety rather than paperwork alone, the decision stops being an ordinary human-resources matter. A statement that a clinician’s return could endanger the clinician or patients is a clinical judgment in substance, whatever its administrative form — and clinical judgment inside a California professional corporation is reserved to the professional entity, not to the management organization that may administer the paperwork around it.

That is why the decision chain matters more than the wording. The question is not whether an administrator may communicate such a decision; plainly one may. The question is whether the professional judgment underlying it was made by the professional corporation before implementation, or supplied afterwards to explain an act already taken. The proper-channel test and the first-decision test answer different halves of that question: the first asks whether the decision travelled through the body actually holding the authority, the second asks whether professional review preceded or followed the operative act.

Neither half can be answered from a communication alone. A letter establishes that a reason was given at a time. It does not establish who held the decision right, what any professional body reviewed, or whether that review was substantive rather than ratificatory. The records that would answer it — committee minutes, written consents, the contemporaneous decision file, the referral path for a fitness-for-duty question — are not in the public record for this project, and this investigation does not infer their contents from the fact that a decision was communicated.

California's Medical Board guidance states that Business and Professions Code section 2400 is intended to prevent unlicensed persons from interfering with or influencing physician professional judgment.

The Board identifies physician-controlled decisions to include:

• diagnostic testing;

• referrals;

• ultimate patient care;

• and how many patients a physician must see or how many hours a physician must work.

It also identifies management decisions that should remain under licensed-physician control when they control medical practice, including:

• selection, hiring, and firing as it relates to clinical competency or proficiency .

The key qualification is the phrase as it relates to clinical competency or proficiency .

Not every termination of a physician is a medical decision.

A professional corporation can use ordinary HR administrators to investigate attendance, payroll, interpersonal conduct, policy compliance, or other nonclinical matters.

An MSO can provide lawful administrative assistance.

But if the operative reason for continued exclusion or termination is:

this physician cannot safely treat patients,

then the investigation must determine whether a licensed CFMG physician independently made or approved that professional judgment.

That is the strongest CPOM-relevant framing currently supported by the record.

It avoids the overbroad proposition that every physician-HR decision must personally be performed by a physician.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

Cfmg’s 2025 physician board is strong contrary evidence to a pure shell theory#

California Secretary of State filings from 2025 identify a physician board consisting of:

• Grady Judson Bazzel, M.D.;

• Richard J. Medrano, M.D.;

• Scott Kennedy, M.D.

This is meaningful.

It demonstrates that CFMG has formal physician directors rather than an openly lay board.

It also distinguishes CFMG from structures in which the MSO itself directly holds board seats in the professional corporation.

The unresolved issue is not whether physicians appear in governance.

It is whether those physician directors were free to act independently where their judgment diverged from Wellpath.

That is why real board minutes, rejected recommendations, stock rights, and conflict procedures matter.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

The bankruptcy did not reorganize CFMG stock through the debtor plan#

Because CFMG was a nondebtor professional corporation, the Wellpath Chapter 11 did not simply convert CFMG stock into lender equity in the manner that debtor-company equity was restructured.

That distinction matters.

Wellpath itself announced in May 2025 that ownership of the reorganized Wellpath enterprise transitioned to a group of current and former lenders.

Public SEC filings by Prospect Capital show that its Wellpath debt was converted into debt and equity positions in New WPCC Parent, LLC . Prospect subsequently reported holdings including Series A Preferred Interests and Class A Common Interests in New WPCC Parent.

Those records illuminate the new ownership of the management enterprise.

They do not establish that New WPCC Parent owns CFMG's physician stock.

The more precise question is:

What happened to the MSA, stock-transfer restrictions, management rights, security interests, and succession mechanisms when the Wellpath management enterprise changed ownership?

That is the post-bankruptcy continuity issue.

The documents that now matter most#

Tier One:

• Every stock-transfer restriction agreement referenced in the 2019 assignment.

• Current CFMG stock ledger.

• Current shareholder agreement.

• Shareholder succession agreements.

• Options, proxies, nominee agreements, powers of attorney.

• CFMG bylaws.

• Company Designee appointments.

• Full Deficit Funding Loan Agreement and amendments.

• UCC-1 financing statements and continuations/terminations.

• Current security agreements.

• Bank signature cards.

• ACH and treasury authorities.

• Deposit-account control agreements.

• 2012 Credit Agreement and successor/refinancing agreements.

• Every MSA amendment since 2012.

• Post-bankruptcy ratification/assumption documents.

• 2025–2026 CFMG board/shareholder minutes.

• Monthly management-company bonus resolutions.

• Management-fee/FMV analyses.

• Current New WPCC Parent capitalization and governance agreements.

Tier Two:

• Intercompany ledgers.

• CFMG general ledger.

• Wellpath management-fee invoices.

• Deficit-funding advance history.

• Insurance/claims agreements.

• IT/data exit provisions.

• county change-of-MSO approval provisions.

• employment/personnel transition restrictions.

• Local Government–California delegation matrix.

• documents showing whether CFMG considered alternative managers during bankruptcy.

The stock-transfer restrictions could explain the succession pattern — but the documents are missing#

The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.

At least three major physician-leadership transitions occurred:

• Fithian era → Herr era;

• Herr era → transitional O'Bryan/Bazzel period;

• Bazzel era → current three-director board.

The unresolved question is whether any of these officer transitions coincided with stock succession.

Questions:

• Did Fithian sell or transfer shares?

• Did Herr acquire shares?

• Did Bazzel acquire shares?

• Were Medrano or Kennedy issued shares?

• Was a single physician shareholder replaced while board offices changed around that person?

• Did Wellpath or its predecessor have contractual approval over the transferee?

• Was stock held subject to a transfer restriction favoring the MSO?

• Did a physician's employment status affect ownership?

Those questions cannot be answered from public officer titles.

The stock documents are necessary.

Primary documents now required to complete the ownership chain#

The next document-production/retrieval priority is:

• CFMG stock ledger from 2012 to present.

• Every issued/cancelled stock certificate.

• Shareholder roster by year.

• Share percentages.

• CFMG shareholder agreements.

• Stock-transfer restriction agreements referenced in 2019 assignment.

• Buy-sell agreements.

• succession agreements.

• options.

• proxies.

• nominee/custodial agreements.

• death/disability succession provisions.

• license-loss succession provisions.

• employment-linked stock provisions.

• retirement/resignation transfers.

• board approvals of every stock transfer.

• shareholder approvals.

• valuations/purchase-price records.

• source of funds for each transfer.

• any MSO consent/veto rights.

• any security interest involving shares.

• all Company Designee appointments.

• bylaws from 2012 to present.

• articles/amendments.

• Statements of Information for every year available.

• board/director minutes.

• shareholder meeting minutes.

• written consents.

• conflict-of-interest policies.

• 2012 MSA approval resolutions.

• 2019 assignment approval resolutions.

• post-bankruptcy MSA ratification/continuation resolutions.

• 2026 Local Government–California authorization records.

Why bankruptcy is a true governance stress test#

The ordinary PC–MSO relationship asks whether a physician-owned professional corporation is genuinely independent while buying administrative support from a management company.

Chapter 11 adds a much harder question:

What does the physician corporation do when its exclusive manager becomes insolvent, enters Chapter 11, changes owners, and reorganizes the operating structure?

For an independent principal, that event should at least create the possibility of:

• evaluating the manager’s solvency;

• assessing contract breach/default rights;

• evaluating alternative managers;

• deciding whether to continue the MSA;

• reassessing management fees;

• obtaining independent legal advice;

• examining data/records continuity;

• considering malpractice and insurance continuity;

• evaluating effects on physician employment;

• approving any required assignment or post-emergence transition;

• and documenting the physician board’s judgment.

A decision to remain with Wellpath could be entirely rational.

The test is not whether CFMG changed managers.

The test is whether CFMG exercised an identifiable independent corporate choice .

To date, this investigation has not identified publicly filed CFMG board minutes, shareholder resolutions, independent-counsel memoranda, or other CFMG-specific governance records documenting such a decision.

That absence must be interpreted cautiously.

CFMG was a nondebtor professional corporation. Its internal board materials were not necessarily required to be filed in the Wellpath bankruptcy.

Thus the correct conclusion is not:

“CFMG’s board did nothing.”

The correct conclusion is:

The public bankruptcy record reviewed to date contains extensive evidence of what Wellpath’s Debtors sought to preserve in the PC relationships, but comparatively little public evidence of what CFMG’s physician board independently decided about continuing that relationship.

That asymmetry itself defines the next documentary inquiry.

The bankruptcy created the best possible opportunity for a CFMG independence test#

The insolvency of an exclusive long-term manager should create an obvious governance question for any independently controlled client corporation.

CFMG’s board could have asked:

• Is the bankruptcy a default?

• Is performance materially impaired?

• Do we have termination rights?

• Should we evaluate another manager?

• Are patient-care services at risk?

• Are county contracts at risk?

• Will our records remain available?

• Will payroll continue?

• Will malpractice coverage continue?

• Does the new lender ownership affect our MSA?

• Do stock-transfer restrictions change?

• Are our financial accounts protected?

• Should management fees change?

• Does CFMG need independent counsel?

It is entirely possible that the CFMG board asked all of these questions and concluded that continued use of Wellpath was clearly best for CFMG and patients.

The public bankruptcy docket simply does not reveal the answer.

That makes the board record unusually probative.

The missing CFMG board record should not be treated as evidence of absence#

Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.

A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.

Therefore:

No public CFMG board minutes found ≠ no CFMG board deliberation occurred.

But where the substantive question is physician independence, those records become the best direct evidence.

The public record should therefore say:

No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.

That is accurate and neutral.

2025 SECRETARY OF STATE FILINGS SHOW A PHYSICIAN BOARD DURING THE BANKRUPTCY ERA#

Project records from the California Secretary of State identify, in January 2025:

• Grady Judson Bazzel — Chief Executive Officer / Director;

• Richard J. Medrano — Secretary / Director;

• Scott Kennedy — Chief Financial Officer / Director.

That means the formal CFMG board during the bankruptcy period was physician-composed.

This is meaningful evidence favoring the formal professional-corporation structure.

It also allows the governance question to be framed concretely:

What did Bazzel, Medrano, and Kennedy decide, in their CFMG capacities, about the Chapter 11 and continuation of the Wellpath MSA?

That is much more useful than asking abstractly whether “CFMG” approved the reorganization.

WHAT WOULD CONSTITUTE STRONG CONTRARY EVIDENCE?#

The following would be substantially more consequential:

• Wellpath or lender documents selecting CFMG’s shareholder successor without meaningful physician choice;

• stock-transfer instruments requiring continuation of Wellpath as manager;

• CFMG board action occurring only after Wellpath implementation;

• automatic continuation of the MSA despite a formal assignment/ownership change requiring consent;

• documents showing the Wellpath side could replace the CFMG owner/director;

• lender covenants directly controlling CFMG governance;

• CFMG unable to terminate the manager without losing its stock, contracts, accounts, records, or operating assets.

No such CFMG-specific document has yet been established publicly in this investigation.

That is precisely why the missing stock and governance instruments matter.

The bankruptcy record sharpens the central cpom question#

The bankruptcy evidence does not prove that Wellpath practiced medicine through CFMG.

It does something more useful.

It reveals the architecture of dependence .

The Debtors themselves described:

• a friendly-PC structure;

• physician ownership;

• deep administrative control;

• major economic reliance on PC revenues;

• stock-transfer restrictions tied to management continuity;

• authority relating to PC licensing/qualification;

• insurance;

• payroll;

• collections;

• taxes;

• legal support;

• indemnification;

• lender notice over new PC contracts.

California law then asks a separate question:

Did those structural rights and dependencies remain on the lawful administrative side of the line, or did they give the nonprofessional management enterprise practical or contractual authority over decisions reserved to physicians?

That question still requires the CFMG-specific stock, board, and authority records.

Article v.f makes the missing stock agreements more, not less, important#

One might initially assume that confirmation rendered the stock-transfer issue irrelevant. The opposite is true.

If the MSA was broadly assumed together with related agreements and interests, then determining the exact scope of the CFMG-related instruments becomes even more important.

The 2019 Assignment expressly links the MSA, related/incidental instruments, and stock-transfer restriction agreements. The bankruptcy PC Motion separately describes stock-transfer agreements as part of the friendly-PC system and says they support continuity of Debtor administrative services. Article V.F then uses broad language about modifications, amendments, supplements, restatements, related agreements, options, rights, and interests.

The convergence of those documents means the CFMG-specific stock instrument should now be treated as a Plan-continuity document , not merely a historical ownership document.

The exact instrument could reveal whether ownership-succession control also crossed the May 9, 2025 restructuring boundary.

Bankruptcy makes the control-instrument question more urgent#

the prior analysis indicates that the CFMG MSA most likely continued through Wellpath’s Chapter 11 under the Plan’s blanket assumption mechanism.

The 2019 assignment also placed stock-transfer restrictions in the Wellpath LLC relationship.

The confirmed Plan contains broad language treating assumed contracts as including related agreements and interests unless separately rejected.

This creates a plausible path by which stock-control rights could have continued after May 9, 2025.

But the precise bankruptcy treatment of the CFMG stock agreement remains unknown.

Questions:

• Was the stock agreement separately scheduled?

• Was it considered an executory contract?

• Was it considered an organizational document?

• Was it amended at emergence?

• Did lender ownership alter any rights?

• Did the physician shareholder sign a reaffirmation?

These questions should be treated as Plan implementation issues, not merely historical corporate questions.

The physician-governance body remains undocumented#

Public corporate records identify CFMG physician directors and officers. Whether the same individuals participated in particular personnel decisions is not established by any public record reviewed here. This analysis therefore does not publish the private worker, date, outcome, or underlying personnel document.

The governance question is nevertheless legitimate and independently testable:

What is the legal source, charter, membership, delegated authority, and decision scope of any CFMG body described as a physician board, physician committee, peer-review body, or comparable professional-governance group?

The answer should be sought in public or otherwise publishable versions of:

• bylaws;

• board resolutions;

• committee charters;

• delegation instruments;

• minutes or written consents filed in litigation;

• credentialing/peer-review governance documents;

• and sworn testimony describing the body's authority.

Until those materials are located, the correct public conclusion is that CFMG has identifiable physician corporate leadership while the relationship among its statutory board, any physician committee, and other professional-governance bodies remains incompletely documented.

A reported physician decision does not, by itself, complete the decision chain#

A governance question can be posed publicly without any private record: if a future public filing, deposition or produced document shows physician participation in a specific personnel decision, that would be direct evidence of professional governance in operation. Until then the question stays open.

The same sequence applies to any public decision event through the same sequence used elsewhere in the series: origin → recommendation → authorized professional review → approval or veto → implementation . A later physician ratification is not the same as an originating decision; a management recommendation is not the same as final authority; and mere alignment does not reveal who would prevail under disagreement.

The highest-value evidence is a conflict-tested record showing that an authorized CFMG physician body could say no and that the enterprise was required to follow its decision—or the reverse. Until such a public record is available, private personnel material should remain a research lead rather than a published merits proposition.

Records with the highest probative value#

• articles of incorporation;

• bylaws, all relevant versions;

• shareholder agreements;

• stock certificates and ledgers;

• stock-transfer restriction agreements;

• succession agreements;

• options;

• proxies;

• voting agreements;

• nominee agreements;

• custodial/escrow agreements;

• death/disability succession instruments;

• buy-sell agreements;

• board/shareholder resolutions approving ownership arrangements;

• 2012 MSA and all exhibits;

• assignment into Wellpath structure;

• every amendment/restatement/waiver;

• deficit-funding agreements;

• collateral/security agreements;

• UCC filings;

• deposit-account control agreements;

• MSA termination notices/rights analyses;

• documents addressing transition away from the manager.

Tier-one open evidence#

The highest-value missing items remain:

• CFMG-specific stock-transfer restriction / succession agreement.

• CFMG stock ledger and shareholder roster by year.

• CFMG bylaws and Company-Designee appointments.

• Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.

• Docket 194 CFMG assumption/cure row and proposed cure amount.

• CFMG board/shareholder minutes from the bankruptcy and emergence period.

• Deficit Funding Loan Agreement.

• UCC/security-interest records.

• Cash/bank signature and treasury authorities.

• Monthly CFMG management-bonus resolutions.

• Smith ECF 156 and full financial-discovery record.

• Full Overfield Chapman termination file/approval chain.

• Utilization-management denial/appeal/override records.

• Current Local Government–California delegation matrix.

• Post-emergence MSA/stock-instrument amendments or reaffirmations.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 024 — Richard Medrano: One Physician, Two Institutional Roles

• Article 026 — Dheeraj Taranath and the Enterprise Clinical Layer

• Article 023 — Judd Bazzel: From Correct Care Clinical Executive to CFMG President

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: What does a physician CFO/director potentially reveal about management fees, bankruptcy, and board oversight? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are physician CFO, financial governance, board oversight, and management economics. The source spine identified in the current public record is: Corporate filings; County signatures; finance/governance questions; bankruptcy-period board-record targets. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Scott Kennedy and the Financial Side of Physician Governance should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. The governing question is narrow: What does a physician CFO/director potentially reveal about management fees, bankruptcy, and board oversight? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Scott Kennedy and the Financial Side of Physician Governance, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate? However, unlike Bazzel and Medrano, the present public source set does not yet permit the investigation to reconstruct Kennedy's pre-CFMG Wellpath/CCS role with equal confidence.

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

Sources and authorities#

1. 2019 Assignment www.prisonlegalnews.org — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf